What is the recommended intravenous infusion protocol for enfortumab vedotin, including dose, schedule, premedication, monitoring, and dose modifications?

Enfortumab Vedotin Infusion Protocol

Administer enfortumab vedotin at 1.25 mg/kg (maximum 125 mg) intravenously over 30 minutes on days 1,8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity. 1

Dosing and Administration

Standard Dosing

• Dose: 1.25 mg/kg (up to maximum 125 mg per dose)
• Schedule: Days 1,8, and 15 of a 28-day cycle
• Infusion duration: 30 minutes via IV line
• Continue until: Disease progression or unacceptable toxicity 1, 2

Preparation Requirements

Reconstitution:

• 20 mg vial: Add 2.3 mL sterile water for injection (final concentration 10 mg/mL)
• 30 mg vial: Add 3.3 mL sterile water for injection (final concentration 10 mg/mL)
• Swirl slowly until dissolved; allow to settle ≥1 minute until bubbles disappear
• DO NOT SHAKE 1

Dilution:

• Transfer calculated dose to infusion bag containing 5% dextrose, 0.9% sodium chloride, or lactated Ringer's
• Final concentration: 0.3-4 mg/mL
• Mix by gentle inversion; DO NOT SHAKE
• Administer immediately or store ≤8 hours at 2-8°C 1

Critical administration points:

• DO NOT administer as IV push or bolus
• DO NOT mix with other medications
• Use dedicated IV line 1

Premedication Strategy

Routine premedication is NOT recommended for enfortumab vedotin monotherapy. 1

However, the evidence presents a critical dilemma:

• Against routine premedication: Recent real-world data shows prophylactic IV dexamethasone (6.6 mg) was associated with significantly worse overall survival (10.3 vs 17.4 months, HR 1.91, p=0.048) despite reducing skin toxicities (10% vs 62.7%, p<0.001) 3
• For selective premedication: ESMO guidelines suggest premedication with paracetamol, antihistamine, and corticosteroid only if prior infusion reaction occurred with similar antibody-drug conjugates like brentuximab vedotin 4

My recommendation: Reserve premedication for patients with documented prior infusion reactions only. The survival detriment associated with routine corticosteroid premedication outweighs the benefit of reduced skin toxicity, which can be managed with dose modifications and topical treatments 3.

Monitoring During Infusion

Monitor for infusion reactions including:

• Redness, swelling, itching at infusion site
• Systemic symptoms: fever, chills, dyspnea
• Extravasation signs 1

Management of infusion reactions:

• Grade 1-2: Slow or interrupt infusion; provide symptomatic treatment; resume at slower rate once stable 4
• Grade 3-4: Stop infusion immediately; aggressive symptomatic treatment; consider permanent discontinuation 4

Dose Modifications

Key Principle

Maintain full dose intensity through at least the first 3 cycles (Days 1-84) whenever possible. Dose modifications before cycle 3 significantly compromise efficacy, while modifications at or after cycle 3 have minimal impact on response duration 5.

Skin Reactions (Most Critical Toxicity)

For Grade 2 persistent/recurrent skin reactions:

• Withhold until Grade ≤1
• Consider topical corticosteroids and antihistamines
• Resume at same or reduced dose 1

For Grade 3 skin reactions:

• Withhold enfortumab vedotin
• Refer for specialized dermatologic care
• Upon resolution to Grade ≤1, may resume at reduced dose
• Discontinue permanently if suspected Stevens-Johnson syndrome or toxic epidermal necrolysis 1

Severe skin reactions occur in:

• 17% with EV + pembrolizumab (median onset 1.7 months)
• 14% with EV monotherapy (median onset 0.6 months)
• Fatal bullous dermatitis reported in 0.2% 1

Peripheral Neuropathy

Grade 2:

• Withhold until Grade ≤1, then resume at same dose
• If recurs, withhold until Grade ≤1 and reduce dose 1

Grade 3:

• Withhold until Grade ≤1, then reduce dose
• If Grade 3 recurs, discontinue permanently 1

Grade 4:

• Discontinue permanently 1

Hyperglycemia

Fasting glucose >250 mg/dL or random glucose >300 mg/dL:

• Withhold until adequate control achieved
• Resume at same dose if controlled within 7 days
• Reduce dose if requires >7 days to control 1

Ocular Disorders

Grade 2-3:

• Withhold until Grade ≤1
• Consider ophthalmology consultation
• Resume at reduced dose 1

Grade 4:

• Discontinue permanently 1

Dose Reduction Schedule

• First reduction: 1.0 mg/kg
• Second reduction: 0.75 mg/kg
• Third reduction: 0.5 mg/kg
• If unable to tolerate 0.5 mg/kg: Discontinue permanently 1

Clinical Context and Efficacy

When combined with pembrolizumab (current first-line standard), enfortumab vedotin demonstrates:

• Median OS: 31.5 months vs 16.1 months with chemotherapy (HR 0.47)
• Median PFS: 12.5 months vs 6.3 months (HR 0.45)
• ORR: 67.7% (29.1% complete response) 6, 7

Critical caveat: 35.5-51.7% of patients require dose reductions, but most maintain therapeutic benefit if modifications occur after cycle 3 5. Early dose reductions or premature discontinuation before cycle 3 compromise outcomes significantly 5.

Common Pitfalls to Avoid

1. Do not routinely premedicate with corticosteroids - associated with worse survival 3
2. Do not reduce dose in first 3 cycles unless absolutely necessary - compromises efficacy 5
3. Do not shake vials or infusion bags - may denature the antibody-drug conjugate 1
4. Do not administer as IV push/bolus - must be 30-minute infusion 1
5. Do not delay aggressive management of Grade 3+ skin reactions - can progress to life-threatening SJS/TEN 1
6. Do not ignore early neuropathy symptoms - easier to manage with early intervention 1